Time: 3 hours, Marks: 100

### **Ph. D Entrance Test**

# **Subject: Pharmacology in Pharmacy**

#### Guidelines:

- 1. Section I consists of 40 multiple choice objective type questions. All are compulsory.
- 2. The section II consists of short answer questions.
- 3. The section III consists of long answer questions.

### Section I

## All questions are compulsory

(40 X 1=40 marks)

- 1) Transdermal drug delivery systems offer the following advantages except:
  - a) They produce high peak plasma concentration of the drug
  - b) They produce smooth and non-fluctuating plasma concentration of the drug
  - c) They minimise interindividual variations in the achieved plasma drug concentration
  - d) They avoid hepatic first-pass metabolism of the drug
- 2) \_\_\_\_\_\_ is a Glycoprotein IIb/IIIa inhibitor.
  - a) Roxifiban
  - b) Aspirin
  - c) Ticlopidine
  - d) Clopidogrel
- 3) Select the drug combination which does not exhibit supraadditive synergism:
  - a) Nalidixic acid + Nitrofurantoin
  - b) Amoxicillin + Clavulanic acid
  - c) Pyrimethamine + Sulfadoxine
  - d) Sulfamethoxazole + Trimethoprim
- 4) For a patient of peptic ulcer, the safest nonopioid analgesic is:
  - a) Celecoxib
  - b) Diclofenac sodium
  - c) Paracetamol
  - d) Ibuprofen

- 5) Atropine produces the following actions except:
  - a) Tachycardia
  - b) Mydriasis
  - c) Dryness of mouth
  - d) Urinary incontinence
- 6) The most vulnerable period of pregnancy for the causation of foetal malformations due to drugs is:
  - a) 18-55 days of gestation
  - b) 56-84 days of gestation
  - c) Second trimester
  - d) 36 weeks onwards
- 7) Presently, the goal of antiretroviral therapy is:
  - a) Eradication of HIV from the body of the patient
  - b) Inhibit viral replication to undetectable levels
  - c) Restore immune competence of the patient to effective level
  - d) Both 'B' and 'C'
- 8) Select the cell cycle nonspecific antineoplastic drug:
  - a) Vincristine
  - b) Bleomycin
  - c) Methotrexate
  - d) 5-Fluorouracil
- 9) The most important drawback of sucralfate in the treatment of duodenal ulcer is:
  - a) Low ulcer healing efficacy
  - b) Poor relief of ulcer pain
  - c) High incidence of side effects
  - d) Need for taking a big tablet four times a day
- 10) Malignant hyperthermia is associated with:
  - a) Ether
  - b) Halothane
  - c) Pentobarbitone
  - d) Midazolam
- 11) The adverse effects of angiotensin converting enzyme II inhibitors are:
  - a) Cough
  - b) Angioedema
  - c) Hypotension
  - d) All of the above

	icoagulants in acute myocardial infarction affords the following benefit(s):
	Reduces short-term mortality
	Prevents thrombus extension and subsequent attack
· · · · · · · · · · · · · · · · · · ·	Prevents venous thromboembolism
d)	All of the above
13) The follow	ving factor(s) is/are required for the absorption of dietary vitamin B <sub>12</sub> :
a)	Gastric acid
b)	Gastric intrinsic factor
,	Transcobalamine
d)	Both 'A' and 'B
14) Aplastic a	nemia with Chloramphenicol is a Type adverse drug reaction.
a)	A STATE STATE OF STAT
,	B
d)	D
15) The curren	nt therapeutic indication of acetazolamide is:
	Congestive heart failure
	Renal insufficiency
,	Cirrhosis of liver
d)	Glaucoma
16) Morphine	is in patients with biliary colic.
	Contraindicated
200 Doy 2	Prescribed
	First line therapy
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Recommended
17) Rebound	nypertension on sudden stoppage of medication is most likely to occur with:
20 AY AV . U A	Hydrochlorothiazide
	Prazosin
DX 450 CO 0 1 X 1	Clonidine
	Lisinopril
	the following drugs is a potassium channel opener:
	Nicorandil
	Hydralazine
YX. PA VA III. On I	Glibenclamide
(d)	Amiloride
\$7.67.67.69.69 \$7.67.69.69	Turn Over

- 19) Warfarin and Phenylbutazone co administration can lead to:
  - a) Drug -drug interaction higher incidences in bleeding
  - b) Drug -drug interaction greater pain relief
  - c) Synergistic effect
  - d) Supraadditive effect
- 20) Bisphosphonates are useful in :
  - a) Osteoporosis
  - b) Asthma
  - c) Neither a nor b
  - d) Both a and b
- 21) Glyceryltrinitrate is administered by the following routes except:
  - a) Oral
  - b) Sublingual
  - c) Intramuscular
  - d) Intravenous
- 22) The principal action common to all class I antiarrhythmic drugs is:
  - a) Na+ channel blockade
  - b) K+ channel opening
  - c) Depression of impulse conduction
  - d) Prolongation of effective refractory period
- 23) The neurotransmitter system in the brain most affected in Alzheimer's disease is:
  - a) Glutaminergic
  - b) Gabaergic
  - c) Dopaminergic
  - d) Cholinergic
- 24) The protective effects of Sodium cromoglycate in asthma is due to:
  - a) Inhibition of degranulation of mast cells
  - b) Blocking of H1 receptors
  - c) Blocking of 5HT receptors
  - d) Bronchodilation
- 25) The antidote of choice for morphine poisoning is:
  - a. Nalorphine
  - b. Nalbuphine
  - c. Naltrexone
  - d. Naloxone

26) The drug i	nhibiting HMG-CoA reductase is:	92000 A
a)	Bezafibrate	
b)	Rosuvastatin	
c)	Nicotinic acid	000000000000000000000000000000000000000
d)	Colestipol	
27) The follow	ving adverse effect can occur even long after withdra	awal of L-Dopa
	Paradoxical tachycardia	
	Tardive dyskinesia	
	Malignant hyperthermia	
d)		
28) Reye's syr	ndrome is associated with viral infection and	use.
a)	Aspirin	
b)	Indomethacin	
c)	Nimesulide	
d)	Paracetamol	
29) Drug of ch	noice in Status epilepticus is:	202 1 D
	Ethosuximide	\$200°
b)	Rivastigmine	DOX O
c)	Amphetamine	
d)	Diazepam	300
30) Allopurino	ol lowers the plasma concentration of:	
a)	Hypoxanthine	
<b>b</b> )	Xanthine	
(c)	Uric acid	
d)	All of the above	
31) The virus	directed reverse transcriptase enzyme is inhibited by	<i>y</i> :B
(a)	Amantadine	
(b)	Zidovudine	
90° (70° (c))	Vidarabine	
(d)	Acyclovir	
32) Therapeut	ic index is:	
a)	LD50/ED50	
(d (2,5%)	MD50/ED50	
(c)	LD50/MD50	
\$ \$ \$ \do d)	ED50/LD50	

33) A dru	g which doe	es not produce	any action b	y itself but	decreases th	e slope of	the log	dose-
respo	onse curve a	nd suppresses	the maximal	response t	o another dru	ig is a:	Y DOS	55 CO N

- a) Physiological antagonist
- b) Competitive antagonist
- c) Noncompetitive antagonist
- d) Partial agonist
- 34) The drug added to an injection of local anesthetic is:
  - a) Acetyl choline
  - b) Epinephrine
  - c) Bupivacaine
  - d) Amphetamine
- 35) Which of the following is teratogenic:
  - a) Thalidomide
  - b) Phenytoin
  - c) Both a and b
  - d) Only a
- 36) Which scale is used to measure causality of adverse effects:
  - a) Naranjo scale
  - b) WHO scale
  - c) Both **a** and **b**
  - d) Neither a and b
- 37) The loading dose of a drug is governed by its:
  - a) Renal clearance
  - b) Plasma half life
  - c) Volume of distribution
  - d) Elimination rate constant
- 38) The most effective drug in Parkinsonism is:
  - a) Bromocriptine
  - b) Selegiline
  - c) Levodopa + carbidopa
  - d) Biperiden
- 39) Phase \_\_\_\_\_ studies are also known as safety and efficacy studies:
  - a) IV
  - b) I
  - c) III
  - d) II

- 40) Select the drug with low therapeutic index:
  - a) Digoxin
  - b) Paracetamol
  - c) Aspirin
  - d) Roxithromycin

### **Section II**

Attempt **any three** (03) questions out of five (05):

(3 X 10=30 marks)

- Q1. Explain the factors which affect bioavailability of a drug? What is the importance of bioavailability and bioequivalence for generic drugs?
- Q2 Discuss the various types of calcium channels and therapeutic areas in which they be modulated.
- Q3. Discuss various methods in pharmacovigilance.
- Q4. Discuss the pharmacotherapy and advances in treatment of: (any two)
  - i. Hyperlipidaemia
  - ii. Diabetes mellitus
  - iii. Parkinson's disease.
- Q5. Discuss the phases of clinical trials and the importance of ethics in clinical trials.

### **Section III**

Attempt **any two** (02) questions out of four (04):

(2 X 15=30 marks)

- Q1. Discuss in detail the pharmacology of drugs modulating the release, synthesis and metabolism of catecholamines.
- Q2. Discuss in detail the G protein-coupled receptor and its signal transduction pathways.
- Q3. Describe the various preclinical models to evaluate nootropic activity of potential drug molecules.
- Q4. Discuss the regulatory guidelines and the tests which are conducted for toxicity studies.

\_\_\_\_\_